PURPOSE: Targeted delivery of alpha-particle-emitting radionuclides is a promising novel option in cancer therapy. We generated stable conjugates of the vascular tumour-homing peptide F3 both with (225)Ac and (213)Bi that specifically bind to nucleolin on the surface of proliferating tumour cells. The aim of our study was to determine the therapeutic efficacy of (225)Ac-DOTA-F3 in comparison with that of (213)Bi-DTPA-F3. METHODS: ID(50) values of (213)Bi-DTPA-F3 and (225)Ac-DOTA-F3 were determined via clonogenic assays. The therapeutic efficacy of both constructs was assayed by repeated treatment of mice bearing intraperitoneal MDA-MB-435 xenograft tumours. Therapy was monitored by bioluminescence imaging. Nephrotoxic effects were analysed by histology. RESULTS: ID(50) values of (213)Bi-DTPA-F3 and (225)Ac-DOTA-F3 were 53 kBq/ml and 67 Bq/ml, respectively. The median survival of control mice treated with phosphate-buffered saline was 60 days after intraperitoneal inoculation of 1 × 10(7) MDA-MB-435 cells. Therapy with 6 × 1.85 kBq of (225)Ac-DOTA-F3 or 6 × 1.85 MBq of (213)Bi-DTPA-F3 prolonged median survival to 95 days and 97 days, respectively. While F3 labelled with short-lived (213)Bi (t (1/2) 46 min) reduced the tumour mass at early time-points up to 30 days after treatment, the antitumour effect of (225)Ac-DOTA-F3 (t (1/2) 10 days) increased at later time-points. The difference in the fraction of necrotic cells after treatment with (225)Ac-DOTA-F3 (43%) and with (213)Bi-DTPA-F3 (36%) was not significant. Though histological analysis of kidney samples revealed acute tubular necrosis and tubular oedema in 10-30% of animals after treatment with (225)Ac-DOTA-F3 or (213)Bi-DTPA-F3, protein casts were negligible (2%), indicating only minor damage to the kidney. CONCLUSION: Therapy with both (225)Ac-DOTA-F3 and (213)Bi-DTPA-F3 increased survival of mice with peritoneal carcinomatosis. Mild renal toxicity of both constructs favours future therapeutic application.
PURPOSE: Targeted delivery of alpha-particle-emitting radionuclides is a promising novel option in cancer therapy. We generated stable conjugates of the vascular tumour-homing peptide F3 both with (225)Ac and (213)Bi that specifically bind to nucleolin on the surface of proliferating tumour cells. The aim of our study was to determine the therapeutic efficacy of (225)Ac-DOTA-F3 in comparison with that of (213)Bi-DTPA-F3. METHODS: ID(50) values of (213)Bi-DTPA-F3 and (225)Ac-DOTA-F3 were determined via clonogenic assays. The therapeutic efficacy of both constructs was assayed by repeated treatment of mice bearing intraperitoneal MDA-MB-435 xenograft tumours. Therapy was monitored by bioluminescence imaging. Nephrotoxic effects were analysed by histology. RESULTS: ID(50) values of (213)Bi-DTPA-F3 and (225)Ac-DOTA-F3 were 53 kBq/ml and 67 Bq/ml, respectively. The median survival of control mice treated with phosphate-buffered saline was 60 days after intraperitoneal inoculation of 1 × 10(7) MDA-MB-435 cells. Therapy with 6 × 1.85 kBq of (225)Ac-DOTA-F3 or 6 × 1.85 MBq of (213)Bi-DTPA-F3 prolonged median survival to 95 days and 97 days, respectively. While F3 labelled with short-lived (213)Bi (t (1/2) 46 min) reduced the tumour mass at early time-points up to 30 days after treatment, the antitumour effect of (225)Ac-DOTA-F3 (t (1/2) 10 days) increased at later time-points. The difference in the fraction of necrotic cells after treatment with (225)Ac-DOTA-F3 (43%) and with (213)Bi-DTPA-F3 (36%) was not significant. Though histological analysis of kidney samples revealed acute tubular necrosis and tubular oedema in 10-30% of animals after treatment with (225)Ac-DOTA-F3 or (213)Bi-DTPA-F3, protein casts were negligible (2%), indicating only minor damage to the kidney. CONCLUSION: Therapy with both (225)Ac-DOTA-F3 and (213)Bi-DTPA-F3 increased survival of mice with peritoneal carcinomatosis. Mild renal toxicity of both constructs favours future therapeutic application.
Authors: N Chouin; K Bernardeau; F Davodeau; M Chérel; A Faivre-Chauvet; M Bourgeois; C Apostolidis; A Morgenstern; A Lisbona; M Bardiès Journal: Radiat Res Date: 2009-06 Impact factor: 2.841
Authors: Jaspreet Singh Jaggi; Surya V Seshan; Michael R McDevitt; George Sgouros; Elizabeth Hyjek; David A Scheinberg Journal: Int J Radiat Oncol Biol Phys Date: 2006-02-28 Impact factor: 7.038
Authors: Jaspreet Singh Jaggi; Surya V Seshan; Michael R McDevitt; Krista LaPerle; George Sgouros; David A Scheinberg Journal: J Am Soc Nephrol Date: 2005-06-29 Impact factor: 10.121
Authors: Yong Li; Emma Song; Syed M Abbas Rizvi; Carl A Power; Julia Beretov; Chand Raja; Paul J Cozzi; Alfred Morgenstern; Christos Apostolidis; Barry J Allen; Pamela J Russell Journal: Clin Cancer Res Date: 2009-02-01 Impact factor: 12.531
Authors: Sandra Heskamp; Reinier Hernandez; Janneke D M Molkenboer-Kuenen; Markus Essler; Frank Bruchertseifer; Alfred Morgenstern; Erik J Steenbergen; Weibo Cai; Christof Seidl; William J McBride; David M Goldenberg; Otto C Boerman Journal: J Nucl Med Date: 2017-02-23 Impact factor: 10.057
Authors: Artem R Khabibullin; Aleksandra Karolak; Mikalai M Budzevich; Mark L McLaughlin; David L Morse; Lilia M Woods Journal: Medchemcomm Date: 2018-06-06 Impact factor: 3.597
Authors: Hua Yang; Justin J Wilson; Chris Orvig; Yawen Li; D Scott Wilbur; Caterina F Ramogida; Valery Radchenko; Paul Schaffer Journal: J Nucl Med Date: 2021-09-09 Impact factor: 11.082
Authors: Mark F McLaughlin; Jonathan Woodward; Rose A Boll; Jonathan S Wall; Adam J Rondinone; Stephen J Kennel; Saed Mirzadeh; J David Robertson Journal: PLoS One Date: 2013-01-18 Impact factor: 3.240